188 related articles for article (PubMed ID: 35674757)
1. A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy, Safety, and Patient Satisfaction of Tretinoin 0.05% Lotion for Chest Rejuvenation.
Wood E; Almukhtar R; Gonzalez A; Angra K; Lipp M; Fabi S
J Drugs Dermatol; 2022 Jun; 21(6):645-652. PubMed ID: 35674757
[TBL] [Abstract][Full Text] [Related]
2. Single-Center, Prospective, Double-Blind, Evaluator-Blind, non-Randomized, Vehicle-Controlled Trial With a 1927 Nm Non-Ablative Fractionated Laser and Topical 0.05% Tretinoin Lotion for Facial Dyspigmentation and Photodamage.
Almukhtar R; Carr E; Angra K; Lipp M; Boesn M; Goldman M
J Drugs Dermatol; 2021 Nov; 20(11):1174-1179. PubMed ID: 34784124
[TBL] [Abstract][Full Text] [Related]
3. Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
Draelos Z; Tanghetti E; Guenin E
J Drugs Dermatol; 2022 Aug; 21(8):875-880. PubMed ID: 35946981
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
Harper JC; Baldwin H; Stein Gold L; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
[TBL] [Abstract][Full Text] [Related]
5. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
Stein Gold L; Pariser DM; Guenin E
J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
[TBL] [Abstract][Full Text] [Related]
6. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
Han G; Armstrong AW; Desai SR; Guenin E
J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
[TBL] [Abstract][Full Text] [Related]
7. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
[TBL] [Abstract][Full Text] [Related]
8. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety.
Lain E; Day D; Harper J; Guenin E
J Drugs Dermatol; 2019 Nov; 18(11):1128-1138. PubMed ID: 31741356
[TBL] [Abstract][Full Text] [Related]
9. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
[TBL] [Abstract][Full Text] [Related]
10. Carboxytherapy Mask as Post Nanofractional Radiofrequency Treatment for Improvement of Facial Skin Quality and Photoaging.
Medrano K; Arruda S; Oza N; Sadick N
J Drugs Dermatol; 2021 Apr; 20(4):461-465. PubMed ID: 33852250
[TBL] [Abstract][Full Text] [Related]
11. Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials.
Tanghetti EA; Werschler WP; Lain T; Guenin E; Martin G; Pillai R
J Drugs Dermatol; 2020 Jan; 19(1):70-77. PubMed ID: 31985914
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris.
Tanghetti EA; Kircik LH; Green LJ; Guenin E; Harris S; Martin G; Pillai R
J Drugs Dermatol; 2019 Jun; 18(6):542. PubMed ID: 31251546
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.
Del Rosso J; Stein Gold L; Tyring S; Zeichner J; Callender V; Draelos Z; Werschler W; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Oct; 21(10):1061-1069. PubMed ID: 36219057
[TBL] [Abstract][Full Text] [Related]
14. Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups.
Stein Gold L; Kircik L; Baldwin H; Callender V; Tanghetti E; Del Rosso J; Zeichner J; Cook-Bolden F; Guenin E
J Drugs Dermatol; 2022 Jun; 21(6):587-595. PubMed ID: 35674760
[TBL] [Abstract][Full Text] [Related]
15. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
Eichenfield LF; Sugarman JL; Guenin E; Harris S; Bhatt V
Pediatr Dermatol; 2019 Mar; 36(2):193-199. PubMed ID: 30656753
[TBL] [Abstract][Full Text] [Related]
16. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
Cook-Bolden FE; Gold MH; Guenin E
J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
[TBL] [Abstract][Full Text] [Related]
17. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.
Aschoff R; Möller S; Haase R; Kuske M
J Drugs Dermatol; 2021 Mar; 20(3):295-301. PubMed ID: 33683070
[TBL] [Abstract][Full Text] [Related]
19. Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
Tanghetti EA; Werschler WP; Lain E; Guenin E; Harris S; Loncaric A; Pillai R
J Drugs Dermatol; 2020 Mar; 19(3):272-279. PubMed ID: 32549090
[TBL] [Abstract][Full Text] [Related]
20. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment.
Leyden JJ; Shalita A; Thiboutot D; Washenik K; Webster G
Clin Ther; 2005 Feb; 27(2):216-24. PubMed ID: 15811485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]